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Abstract
Objective Midodrine hydrochloride is a short-acting pres-
sor agent that raises blood pressure in the upright position
in patients with orthostatic hypotension. The US Food and
Drug Administration’s Subpart H approval, under which
midodrine was initially approved, requires post-marketing
studies to confirm midodrine’s clinical benefit in this
indication. The purpose of this study was to evaluate the
clinical benefit of midodrine with regard to symptom
response.
Methods This was a double-blind, placebo-controlled,
randomized, crossover, multicenter study (NCT01518946).
Following screening, patients aged C18 years with severe
symptomatic orthostatic hypotension and on a stable dose
of midodrine for at least 3 months were randomized to
treatment with either their previous midodrine dose or
placebo on day 1 and the respective alternate treatment on
day 2. The primary endpoint measured time to syncopal
symptoms or near-syncope using a 45-min tilt-table test at
1 h post-dose.
Results Thirty-three patients were screened for inclusion:
19 received at least one dose of midodrine and had at least
one post-dose measurement of the primary endpoint. The
least-squares mean time to syncopal symptoms or near-
syncope after tilt-table initiation (mean ± standard error)
was 1626.6 ± 186.8 s for midodrine and 1105.6 ± 186.8 s
for placebo (difference, 521.0 s; 95 % confidence interval
124.2–971.7 s; p = 0.0131). There were 15 adverse events
in 10 patients; all of these were mild or moderate in
severity, with none considered by the investigators to be
related to midodrine.
Interpretation Midodrine is a well-tolerated and clinically
effective treatment for symptomatic orthostatic
hypotension.
Keywords Midodrine  Orthostatic hypotension  Clinical
trial
Introduction
Patients with orthostatic hypotension experience a reduc-
tion in blood pressure when they stand up, which can result
in clinical symptoms of dizziness, blurring of vision,
fainting, and falls [1, 2]. The condition can have a sub-
stantial impact on health-related quality of life [1, 3].
Several therapies have been used for its treatment,
including fludrocortisone, methylphenidate, ephedrine,
indomethacin, and dihydroergotamine [1, 4]. However,
none of these agents are indicated for the condition, and
they are also associated with various adverse events.
Droxidopa, a prodrug metabolized to norepinephrine, was
approved by the US Food and Drug Administration (FDA)
in 2014 for the treatment of orthostatic dizziness, light-
headedness, or near-syncopal feelings in adult patients with
symptomatic neurogenic orthostatic hypotension, but its
effectiveness has not been established beyond 2 weeks of
treatment [5].
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Midodrine hydrochloride, a prodrug for the active
metabolite desglymidodrine, received conditional approval
in the USA in 1996 for the treatment of orthostatic
hypotension [6]. Desglymidodrine is an alpha-1 agonist
that increases blood pressure and vascular tone via stimu-
lation of arterial and venous alpha-adrenergic receptors [6].
It does not stimulate cardiac beta-adrenergic receptors and,
owing to its poor diffusion across the blood–brain barrier,
generally has no effect on the central nervous system [6].
The pressor effects of midodrine occur within approxi-
mately 1 h of the oral administration of a single dose, and
the effects usually persist for about 4 h [6, 7].
Studies conducted in the USA [3, 8] and elsewhere
[6, 9, 10], which included over 4000 patients, have shown
midodrine HCl to be of value in the treatment of orthostatic
hypotension. The FDA’s accelerated Subpart H approval of
midodrine in 1996 considered a decrease in the frequency
of the reductions in blood pressure that occur after standing
in patients with orthostatic hypotension to be a ‘‘surrogate
marker of effectiveness’’ that would likely ‘‘correspond
to a clinical benefit’’. Midodrine has been shown to
increase blood pressure and vascular tone and to reduce
the frequency and severity of syncopal symptoms in
patients with orthostatic hypotension [11, 12], but full
approval of the drug requires post-marketing studies to
confirm that midodrine provides a clinical benefit for
patients with symptomatic orthostatic hypotension [2, 13].
The objective of this phase 4 study was to assess the
effect of midodrine on symptom response in the form of
time to onset of syncopal symptoms or near-syncope
measured using a protocol-defined tilt-table test at 1 h post-
dose.
Methods
Study overview and participants
This was a double-blind, placebo-controlled, randomized,
crossover, multicenter study conducted at six sites in the
USA from 14 May 2012 to 22 June 2013. The study was
carried out in an inpatient setting. Men and women aged
18 years or older who had a documented history of
severe symptomatic orthostatic hypotension (e.g., due to
Parkinson’s disease, Shy–Drager syndrome, multiple
system atrophy, pure autonomic failure, or autonomic
neuropathies) were eligible for enrollment. To be eligible
for inclusion, individuals had to have been on a
stable dose of midodrine for at least 3 months, been
ambulatory when receiving adequate therapy for their
symptomatic orthostatic hypotension, and had at least one
of the following symptoms while standing or when not on
treatment: dizziness, lightheadedness, feeling faint, or
feeling like they might lose consciousness.
Additional eligibility criteria were: women of child-
bearing potential must have had a negative serum beta
human chorionic gonadotropin pregnancy test and must
have abstained from sexual activity that could have
resulted in a pregnancy or had agreed to use accept-
able contraceptives throughout the period of the entire
study and for 30 days after the last dose of midodrine;
willingness and ability to undergo the procedures required
by the protocol, including inpatient stay as required;
adequate hydration status (as assessed by physical
examination and clinical laboratory parameters, e.g., urine
specific gravity); and ability to provide written, signed,
and dated informed consent to participate in the study.
Patients who had completed a previous midodrine study
(SPD426-405; NCT01515865), which had the same
entry criteria and assessments of the severity of symp-
tomatic orthostatic hypotension as the current study,
could enter the randomized phase of this study within
28 days of discharge from SPD426-405 without repeat-
ing screening assessments or within 2 months without
repeating symptom severity assessments.
Patients were not eligible to participate in the study
if they: were pregnant or lactating; had pre-existing
sustained supine hypertension (two measurements at
least 5 min apart with the patient continuously supine
and at rest) greater than the drug label-recommended
level (systolic blood pressure[180 mmHg, diastolic
blood pressure[110 mmHg) or had these measurements
at the screening visit; were using other medications,
unless approved by the study physician; had a clinically
significant clinical laboratory test abnormality during
screening; had participated in other studies of investi-
gational drugs or devices in the 30 days before enroll-
ment in this study (other than study SPD426-405); had
current or relevant history of physical or psychiatric
illness, any medical disorder that may have required
treatment or made the patient unlikely to comply fully
with the requirements of the study or to complete the
study, or any condition that presented undue risk from
midodrine or study procedures; had a concurrent chronic
or acute illness, disability, or other condition (including
significant unexpected laboratory or ECG findings) that
might have confounded the results of the tests and/or
measurements administered in this study, or that might
have increased the risk to the patient; had known or
suspected intolerance or hypersensitivity to midodrine,
closely-related compounds, or any of the stated ingre-
dients; had a prior enrollment failure or randomization in
this study; or had a history of alcohol abuse or other
substance abuse within the last year.
270 Clin Auton Res (2016) 26:269–277
123
Study design
The study began with an open-label screening period of
28 days, during which patients continued their usual, pre-
study midodrine dose (Fig. 1). Baseline assessments of the
severity of symptomatic orthostatic hypotension were
undertaken on day -1, and midodrine treatment was
withdrawn on day 1 (Part A). Participants were eligible to
enter the double-blind, randomized, crossover period (Part
B) if the following criteria were met: (1) increase of at least
4 points in Orthostatic Hypotension Symptom Assessment
Item 1 (OHSA) questionnaire [14] score between day -1
and day 1; (2) no syncopal or near-syncopal event or, at
most, mild orthostatic symptoms within 15 min after
transitioning from supine to standing on day -1 and syn-
cope or a near-syncopal event or more numerous or more
severe orthostatic symptoms on day 1; and (3) decreases in
standing systolic blood pressure of at least 20 mmHg and
standing diastolic blood pressure of at least 10 mmHg
within 15 min after transitioning from the supine to the
standing position on day 1. Physicians and investigators
assessed the patients’ physical and mental wellbeing and
ensured that patients were able to complete the OHSA
questionnaires on both days.
Eligible patients were randomized for Part B in a 1:1 ratio
to one of two treatment sequences: midodrine HCl followed
by placebo, or placebo followed by midodrine HCl. The
randomization number assigned to each patient was obtained
from interactive response technology, which was managed
by an external vendor (Bracket, Langhorne, PA). Random-
ization typically occurred after qualification on day 1, and
the first randomized dose was administered on day 2.
During the double-blind phase (Part B), patients were
treated with midodrine or placebo on day 2, according to
their previous dose, and underwent a tilt-table test at 1 h
post-dose. On day 3, they were given the respective alter-
nate treatment and again underwent a tilt-table test at 1 h
post-dose. Patients were discharged on day 4, and their
previous midodrine dose was reinstated. They were then
followed up for 5–7 days.
The study protocol, any protocol amendments, the final
approved informed consent document, relevant supporting
information, and all types of patient recruitment
Fig. 1 Study design. This was a double-blind, placebo-controlled,
randomized, crossover, multicenter study. After an open-label
screening period of 28 days, during which patients continued their
usual, pre-study midodrine dose, baseline assessments of the severity
of symptomatic orthostatic hypotension were undertaken on day -1.
Midodrine treatment was withdrawn on day 1 (Part A) after which
eligible participants entered the double-blind, randomized, crossover
period (Part B). Patients were discharged on day 4, and their previous
midodrine dose was reinstated. They were then followed up for
5–7 days
Table 1 Study participant characteristics in the final analysis set
Characteristics Total (N = 19)







Native American or Native Alaskan 1 (5.3)
Body mass index (kg/m2) 26.7 ± 6.1





Diagnostic historya Total (N = 14)
Cancer 3 (21.4)
Depression 5 (35.7)
Diabetes/insulin resistance 2 (14.3)







Data are presented as mean ± standard deviation or n (%)
a Diagnostic history not recorded for all patients
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information were submitted and approved by site-specific
institutional review boards and regulatory agencies (as
appropriate) prior to study initiation. The study was con-
ducted in accordance with the International Conference on
Harmonisation of Good Clinical Practice and the principles
of the Declaration of Helsinki, as well as other applicable
local ethical and legal requirements. Patients provided
written informed consent before taking part in any study-
specific procedures.
Tilt-table test procedure
At 1 h post-dose, participants lay supine on a tilt table for
30 min. The table was then tilted from 0 degrees (hori-
zontal) to 90 degrees (vertical, with head up) in 30 s and
was maintained in that position for 45 min or until the
primary endpoint was reached. Time to endpoint was
recorded. If no event occurred within 45 min, 2700 s was
recorded as the time to primary endpoint. To ensure
blinding, although institutional safety protocols may have
required the assessment of vital signs, blood pressure
measurements were not available to the blinded study staff,
and orthostatic blood pressure data were not used to eval-
uate the primary endpoint.
Endpoints
The primary endpoint was the time to onset of syncopal
symptoms or near-syncope (participants felt sufficiently
dizzy, lightheaded, faint, or as if they were about to lose
consciousness so that they requested the table to be
returned to horizontal, or they looked to be about to lose
consciousness based on investigator assessment) during the
tilt-table test.
Safety assessments included adverse events, vital signs,
clinical laboratory parameters, electrocardiograms (ECGs),
and physical examination.
Analysis sets
Three analysis sets were defined for use in this study
(Fig. 2). The enrollment set comprised all patients enrolled
in the study who participated in assessments on day -1
and day 1. The randomized set comprised all patients
enrolled in the study who received at least one dose of
midodrine in Part B. The final analysis set comprised all
patients enrolled in the study, who received at least one
dose of midodrine and had at least one post-dose mea-
surement of the primary endpoint.
Fig. 2 Participant flow. Thirty-three patients were screened for
inclusion in the study and participated in the assessments on
day -1 and day 1; of these, nine did not meet the inclusion criteria.
The enrollment set comprised 24 participants. Four patients were
withdrawn from the study during Part A. The randomized set
comprised the 20 participants who received at least one dose of
midodrine in Part B. One participant did not complete the study
because of technical problems with the tilt-table on day 2 and was
excluded from the final analysis set
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Sample size determination and statistical analysis
Assuming a standard deviation of 240 s for the within-
patient difference in time to onset of syncopal symptoms or
near-syncope, a power level of 80 % and a significance
level of 0.05 (two-sided), it was calculated that the primary
endpoint would need to be assessed in approximately 18
patients (9 patients in each treatment sequence) to detect a
treatment difference of 180 s between treatments.
Summary statistics for the within-patient differences
between treatments (midodrine minus placebo) in time to
onset of syncopal symptoms or near-syncope were calcu-
lated. A Shapiro–Wilk test for normality was applied to the
within-patient differences, and the resulting p value
determined whether analysis of variance (ANOVA) or a
non-parametric procedure, i.e., the Wilcoxon signed-rank
test as suggested by Koch [15], should be used for the
primary analysis.
For the ANOVA procedure, least-squares mean, stan-
dard error, difference in LS mean (midodrine HCl–pla-
cebo) and p value were based on type III sum of squares
from an ANOVA model for time to onset of syncopal
symptoms/near-syncopal symptoms, including treatment
sequence (two levels), treatment (two levels), and treat-
ment period (two levels) as fixed effects and subject-
within-sequence as a random effect.
All analyses were performed using SAS version 9.1.3
or higher (SAS Institute, Cary, NC, USA).
Results
Study enrollment
In total, 33 patients were screened for inclusion in the
study; of these, nine did not meet the inclusion criteria.
Therefore, the enrollment set comprised 24 participants, of
whom seven had previously completed study SPD426-405.
Four patients were withdrawn from the study during Part A
due to enrollment failure (two patients) or not meeting
criteria for continuation to Part B (two patients). Therefore,
the randomized set comprised 20 participants. One partic-
ipant did not complete the study because of technical
problems with the tilt-table on day 2 and was excluded
from the final analysis set.
Patient characteristics and demographics
The 19 patients in the final analysis set had a mean age of
43.5 years (range 18–78 years, Table 1), with 42.1 % under
40 years and 42.1 % aged between 40 and 65 years. Patients
were predominantly female (94.7 %) and white (84.2 %),
and had a mean body mass index of 26.7 kg/m2 [standard
deviation (SD): 6.1; Table 1]. Demographics were similar in
the randomized set (data not shown). Patients’ first daily
dose of midodrine ranged from 2.5 mg to 15 mg.
Supine and orthostatic blood pressure
Blood pressure was recorded during part A of the study on
days-1 (with midodrine) and 1 (without midodrine)
(Table 2). High ([160 mmHg) supine systolic blood
pressure was recorded in two patients on day -1 and in
one of these patients on day 1. One patient experienced
high ([100 mmHg) supine diastolic blood pressure on day
-1. No incidences of supine hypertension were recorded
during Part B of the study, and blood pressure measure-
ments were not assessed during the tilt-table test to ensure
that blinding was maintained.
Primary endpoint
The least-squares (LS) mean time to onset of syncopal
symptoms or near-syncope (mean ± standard error [SE])
Table 2 Supine and orthostatic blood pressure with (day -1) and without (day 1) midodrine in the randomized set
With midodrinea Without midodrine
n Systolic (mmHg) Diastolic (mmHg) n Systolic (mmHg) Diastolic (mmHg)
Supine orthostatic 20 119.4 ± 22.19 72.4 ± 12.91 20 116.5 ± 16.35 71.7 ± 13.97
3 min 20 106.8 ± 20.89 70.0 ± 15.57 18 100.6 ± 14.87 68.1 ± 14.07
5 min 19 107.7 ± 19.93 70.7 ± 15.53 16 95.0 ± 17.10 62.6 ± 14.71
7 min 18 105.1 ± 16.15 72.1 ± 14.22 10 94.9 ± 12.44 62.6 ± 12.00
9 min 17 103.8 ± 19.97 72.6 ± 15.97 9 89.6 ± 14.00 56.3 ± 9.17
11 min 16 106.8 ± 19.43 74.1 ± 16.30 5 94.8 ± 13.01 57.2 ± 5.17
13 min 16 104.1 ± 18.62 73.8 ± 14.90 3 91.3 ± 7.02 57.3 ± 5.03
15 min 16 103.9 ± 18.78 73.9 ± 15.12
Data are presented as mean ± standard deviation
a Patients’ own midodrine
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was 1626.6 ± 186.8 s after initiation of the tilt-table test
in patients receiving midodrine and 1105.6 ± 186.8 s in
patients receiving placebo (Table 3). The Shapiro–Wilk
test for normality was applied to the within-patient
difference between treatments (midodrine HCl–placebo).
The resulting p value of 0.2672 confirmed the normal
distribution of the patient population, and the ANOVA
model was used as described for subsequent analysis. No
statistically significant differences were related to the
treatment sequence (p = 0.5035) or the treatment period
(p = 0.9811).
The difference in LS means between the treatments was
statistically significant (mean difference: 521.0 s, 95 %
confidence interval: 124.2–971.7 s; p = 0.0131), thus
meeting the primary endpoint. In total, six patients
receiving midodrine and one patient receiving placebo did
not have syncopal symptoms or a near-syncope event
during the 45-min tilt-table test.
Safety evaluation
No midodrine-related incidences of supine hypertension
were recorded. Eight patients in the enrollment set
experienced a total of 11 treatment-emergent adverse
events (TEAEs) in Part A, all of which were mild or
moderate in severity and none of which was considered by
the investigator to be related to midodrine. The most
frequent TEAEs were nausea and headache (two patients
experiencing two events in both instances).
Two patients experienced a total of four TEAEs in Part B,
all of which were mild or moderate in severity and none of
which was considered by the investigator to be related to
midodrine. One patient experienced a TEAE of back pain
after receiving placebo, and one patient experienced three
TEAEs (fatigue, flushing, and hot flush) after receiving
midodrine. There were no notable concerns related to clin-
ical laboratory evaluations, ECG results, or health status.
Table 3 Analysis of within-
patient differences in time to
onset of syncopal symptoms or
near-syncope after initiation of a
tilt-table test in patients
receiving midodrine or placebo
in the final analysis set
Placebo Midodrine
Day 2 (N) 9 10
Completed tilt-table test, n/N (%) 1/9 (11.1) 3/10 (30.0)
Time to onset (seconds)a
Mean ± SE 1218.2 ± 253.15 1518.5 ± 314.94
Median (95 % CI) 1136.0 (634.5–1802.0) 1279.0 (806.1–2230.9)
Range 252–2700b 299–2700b
Day 3 (N) 10 9
Completed tilt-table test n/N (%) 0/10 (0) 3/9 (33.3)
Time to onset (seconds)a
Mean ± SE 993.0 ± 162.82 1734.7 ± 301.80
Median (95 % CI) 1163.0 (624.7–1361.3) 1870.0 (1038.7–2430.6)
Range 198–1690 455–2700b
Overall time to onset (seconds)a
n 19 19
Mean ± SE 1099.7 ± 145.50 1620.9 ± 214.30
Median (95 % CI) 1136.0 (794.0–1405.4) 1560.0 (1170.7–2071.1)
LS Mean ± SEc 1105.6 – 186.82 1626.6 – 186.82
Difference in LS Mean (95 % CI) 521.0 (124.2–917.7)
Sequence effect p valuec 0.5035
Period effect p valuec 0.9811
Treatment effect p valuec 0.0131
Bold values indicate the primary endpoint
ANOVA analysis of variance, CI confidence interval, HCl hydrochloride, SD standard deviation, SE stan-
dard error of mean, LS least squares
a The time to onset of syncopal symptoms/near-syncopal symptoms was defined as the duration (in sec-
onds) from the initiation of the protocol-defined tilt-table test until syncopal symptoms/near-syncope (of
sufficient severity that caused the patient to ask that the tilt table be returned to the horizontal position)
b For patients who completed the tilt-table test and did not achieve onset of syncopal symptoms/near-
syncope, the time to onset was set to 2700 s
c LS Mean, standard error, difference in LS mean (midodrine HCl–placebo) and p value were based on
type III sum of squares from an ANOVA model for time to onset of syncopal symptoms/near-syncopal
symptoms, including treatment sequence (two levels), treatment (two levels), and treatment period (two
levels) as fixed effects and subject-within-sequence as a random effect
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Discussion
This study used a randomized-crossover design to
assess the clinical benefit of midodrine in terms of
symptom response compared with placebo in patients
with symptomatic orthostatic hypotension. Symptoms
were induced in a controlled inpatient setting using a
45-min tilt-table test that was performed at 1 h post-dose
with midodrine or placebo. Treatment with midodrine
provided a statistically significant increase in time to
tilt-table-induced syncopal symptoms or near-syncope in
patients with symptomatic orthostatic hypotension when
compared with placebo.
Changes in blood pressure correlate with the frequency and
severity of syncopal symptoms in patients with orthostatic
hypotension, and this has been used as a surrogate measure of
the effectiveness and clinical benefit of orthostatic hypoten-
sion treatments. Midodrine has previously been shown to
increase blood pressure and vascular tone, which correlates
with a reduction in frequency and severity of syncopal
symptoms [11, 12]. Further studies were required to evaluate
midodrine’s clinical benefit with regard to symptom response.
In the present study, patients responding well to midodrine
treatment (stable dose for at least 3 months) were enrolled.
Midodrine-related blood pressure changes and improvement
in OHSA scores in part A of the study served to identify those
patients for whom midodrine provided a clear clinical benefit.
Subsequent analyses during part B demonstrated the mido-
drine-related symptomatic improvement of these patients in a
controlled clinical setting.
A history of severe orthostatic hypotension was one of the
primary criteria for enrolment in the study, and according to
the selection process for part B of the study, the patients
were required to exhibit a[4 point decrease in their OHSA
score and an acute drop in orthostatic blood pressure on
withdrawal of midodrine, confirming the severity of their
hypotension. Although a mean tilt time of 1105 s with
placebo may seem long for patients with this disease, the
majority of patients were being managed with multimodal
treatment. Within this trial, patients were able to maintain all
other treatments, such as fludrocortisone, which may have
influenced the seemingly long time to response in the pla-
cebo group. Interestingly, as shown in Fig. 3, the patients
who had a longer tilt time with placebo seemed to exhibit
greater improvement with midodrine than those patients
with shorter placebo tilt times of\10 min. As this patient
population had been under treatment for at least 3 months
and the study was focussed on evaluating the symptomatic
response in patients with a confirmed midodrine-related
clinical benefit, an expectation of similar results for typical
patients with immediate-onset (\1–2 min) symptomatic
orthostatic hypotension is unlikely.
Midodrine has been associated with supine hyperten-
sion, and there is no clinical trial experience in patients
with supine blood pressure greater than 180/110 mmHg.
Systolic pressure of about 200 mmHg was observed in
13.4 % of patients taking 10 mg midodrine, seemingly
associated with a mean pre-treatment supine systolic blood
pressure of 170 mmHg. Midodrine is not recommended for
use in these patients, and to ensure the safety of patients
enrolled in the study, the cut-off value for supine blood
pressure (C180/110 mmHg) was applied as an exclusion
criterion. As only patients who had been on a stable dose
for at least 3 months were included, the toleration of
midodrine in the population was likely to be quite high. No
incidences of supine hypertension were reported, none of
the adverse events reported were considered to be related to
midodrine, and no new safety signals were identified.
The primary diseases underlying orthostatic hypotension
include Parkinson’s disease, pure autonomic failure, and
multiple system atrophy, although non-neurogenic causes
are more common and may be related to dehydration, drug
therapy, and cardiovascular abnormalities [16]. Many
patients with orthostatic hypotension have comorbidities
related to autonomic nervous system dysfunction, such as
cognitive impairment and diabetes mellitus [17]. These
Fig. 3 Time to onset of syncopal symptoms/near-syncope after
initiation of a tilt-table test in patients receiving midodrine or placebo
in the final analysis set The time to onset of syncopal symptoms/near-
syncopal symptoms was defined as the duration (in seconds) from the
initiation of the protocol-defined tilt-table test until syncopal symp-
toms/near-syncope (of sufficient severity that caused the patient to ask
that the tilt table be returned to the horizontal position). For patients
who completed the tilt-table test and did not achieve onset of syncopal
symptoms/near-syncope, the time to onset was set to 2700 s. The
p value was based on type III sum of squares from an ANOVA
(analysis of variance) model for time to onset of syncopal symptoms/
near-syncopal symptoms, including treatment sequence (two levels),
treatment (two levels), and treatment period (two levels) as fixed
effects and subject-within-sequence as a random effect
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comorbidities display intra- and inter-day variations in
intensity and could impact the assessment of the efficacy of
midodrine versus placebo. In this study, the enrolment
criteria were related primarily to the history and assessed
severity of orthostatic hypertension and not the underlying
diagnosis. As a result, the patient population included
patients who were diagnosed with orthostatic hypotension
at a younger age, who, thus, may have otherwise been
excluded from previous phase 3 clinical trials; this included
patients with depression, diabetes, Ehlers-Danlos syn-
drome, hypothyroidism and cancer, as well as patients with
primary dysautonomias. Patients with orthostatic
hypotension are usually elderly, with prevalence increasing
with age (10–30 % in the elderly), and study enrollments
usually reflect this [18]. However, studies have also shown
a prevalence of 5.1–6.2 % in middle-aged patients [19, 20],
with increased mortality risk in patients with orthostatic
hypotension younger than 42 years [21]. By evaluating a
real-world population in which the patients’ ages ranged
between 18 and 78, the benefit provided by clinical
application of midodrine with regard to patients’ symptoms
and individual responses could be demonstrated in a con-
trolled environment for a heterogeneous population, with a
wide age distribution and a range of associated diagnoses.
Although the use of tilt-testing as implemented in this
study is quite different from real-life situations, midodrine
was highly efficacious in this controlled clinical setting. A
previous midodrine study reported that improved hemo-
dynamic responses to a tilt-table test were associated with
reductions in the symptoms of hypotension and with
improvements in health-related quality of life [22]. Mido-
drine is clearly beneficial in the studied environment, but
more detailed analyses would give greater insight into the
effect on the patients’ quality of life.
Developing effective therapies for orthostatic
hypotension is vitally important as it greatly affects a
patient’s day-to-day functioning: it can be associated
with increased incidence of heart failure, cerebrovascular
disease, myocardial infarction, and falls [19, 23, 24], and
some studies suggest that it can also cause cognitive
impairment [25]. Orthostatic hypotension is difficult to
treat, particularly as orthostatic stress is not uniform
throughout the day [1]. In addition, treatments that ele-
vate standing blood pressure may cause problems, such
as severe supine hypertension [26]. Many commonly
recommended therapies used in the treatment of ortho-
static hypotension have a limited evidence base and lack
high-quality data from randomized, controlled clinical
trials [27]. The results of this study are supportive of
earlier investigations into the efficacy of midodrine
treatment for orthostatic hypotension, which assessed a
variety of dosing frequencies and concentrations
[11, 12]; these randomized, placebo-controlled, double-
blind studies reported that the proportions of patients
experiencing an improvement in standing systolic blood
pressure and a reduction in the major symptoms of
orthostatic hypotension (dizziness or lightheadedness,
and unsteadiness) were significantly larger after receiv-
ing midodrine than after receiving placebo.
The range of orthostatic symptom severity is extremely
wide, and the same treatments are not suitable for all
patients. Patients with mild symptoms can be well treated
with intravascular volume repletion or support stockings,
while patients with more severe symptoms require much
more aggressive medical management [1]. In addition to
the previously reported physiological effect of sustaining
blood pressure in patients with symptomatic orthostatic
hypotension [7, 11, 12], this study has shown that mido-
drine offers a clinical benefit with regard to its efficacy in
prolonging symptom-free orthostasis. As a clinically
effective and well-tolerated treatment for symptomatic
orthostatic hypotension, midodrine is an important treat-
ment option for those patients who are not adequately
treated using simpler measures.
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